![Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.](/sites/default/files/styles/top_stories/public/2018-08/olderpatient-doctor.jpg.webp?itok=Cv18wcDr)
Transcatheter aortic valve replacement (TAVR) is a safe and effective treatment option for patients with inflammatory bowel disease (IBD), according to new findings published in the American Journal of Cardiology.
“IBD includes two main entities—Crohn’s disease and ulcerative colitis,” wrote lead author Agam Bansal, MD, a specialist with the Cleveland Clinic’s Heart and Vascular Center, and colleagues. “The chronic inflammatory state associated with IBD is a significant risk factor predisposing to a prothrombotic state and increased mortality. We utilized the national cohort to understand the differences in the characteristics and clinical outcomes of patients who underwent [TAVR] with and without IBD.”
The study’s authors examined data from more than 91,000 TAVR patients who received care in the United States from 2016 to 2017. Overall, 0.48% of those patients had IBD, and they were more likely to be men than women. The rates of comorbidities such as congestive heart failure, diabetes, hypertension, carotid artery disease, peripheral vascular disease, chronic kidney disease and atrial fibrillation were all similar between TAVR patients with and without IBD.
Researchers noted that there were “no significant differences” in in-hospital mortality, stroke, acute kidney injury, sepsis, the need for mechanical ventilation, new pacemaker implantation or hospitalization charges between the two groups.
IBD patients do face certain risks that could potentially affect their health after undergoing TAVR, but Bansal et al. emphasized that patients who are going to undergo the procedure are “carefully selected by the heart team.”
“To the best of our knowledge, this is the first study to compare the outcomes of TAVI in IBD patients,” the team added.
Click here to read the full study.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.